Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
Satellos (NASDAQ: MSLE) will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, in Toronto. CEO Frank Gleeson will present on April 21 at 11:30 a.m. ET and CEO Gleeson and CFO Liz Williams will hold one-on-one meetings April 21-22.
The live presentation will be available via webcast on the company’s Events and Presentations page, with a replay accessible after the session.
Positive
- None.
Negative
- None.
News Market Reaction – MSLE
In the Apr 9 session, MSLE declined 0.80%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Earnings and financing | Positive | -10.7% | 2025 results, US$57.2M financing, Nasdaq listing, Phase 2 initiations. |
| Mar 10 | Clinical data update | Positive | -18.1% | Interim SAT-3247 clinical and biomarker data in DMD and FSHD models. |
| Feb 24 | Conference presentations | Neutral | +0.6% | Planned oral and poster presentations at 2026 MDA conference. |
| Feb 18 | KOL event announcement | Neutral | -1.5% | Virtual KOL event on DMD and SAT-3247 program details. |
| Feb 17 | Investor conferences | Neutral | -0.6% | Participation in multiple investor conferences with webcasts and meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and financial updates were followed by negative price moves, while routine event and conference announcements saw relatively muted, mixed reactions.
Over the last two months, Satellos reported 2025 financials with a US$57.2M equity financing and Nasdaq listing on Feb 6, 2026, alongside progress into two Phase 2 SAT-3247 trials, yet shares fell after that update. Subsequent interim SAT-3247 data at the 2026 MDA Conference also preceded a double-digit decline. By contrast, announcements of upcoming KOL and investor conference events in February–March 2026 produced only small, mixed price changes, framing today’s Bloom Burton conference notice as part of that ongoing outreach cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.
Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.
2026 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Tuesday, April 21
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website, and a replay will be available following the presentation.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to address deficits in muscle repair and regeneration. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental stem cell driven process that is disrupted in DMD and other degenerative conditions. By addressing the loss in a dystrophin-independent manner, SAT-3247 may re-establish the biochemical signals needed to support muscle regeneration, with potential broad applicability as either a stand-alone or adjunctive therapy. Satellos has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.
CONTACTS
Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com
